FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:288-293 August 3, 1995 Number 5 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background fabry's disease is an x-linked recessive disorder that results from a deficiency of -galactosidase. Left ventricular hypertrophy is one of the common manifestations in men with classic hemizygous disease. Recently, several cases of an atypical variant of hemizygous Fabry's disease, with manifestations limited to the heart, have been reported. Therefore, we assessed the incidence of hemizygosity for Fabry's disease among male patients with left ventricular hypertrophy.

Methods We measured plasma -galactosidase activity in 230 consecutive male patients with left ventricular hypertrophy. Clinical manifestations were assessed, endomyocardial biopsies were performed, and the patients were screened for mutations in the -galactosidase gene.

Results Seven of the 230 patients with left ventricular hypertrophy (3 percent) had low plasma -galactosidase activity (4 to 14 percent of the mean value in normal controls). These seven unrelated patients, ranging in age from 55 to 72 years, did not have angiokeratoma, acroparesthesias, hypohidrosis, or corneal opacities, which are typical manifestations of Fabry's disease. Endomyocardial biopsy was performed in five patients and revealed marked sarcoplasmic vacuolization in all five. samples from four patients were examined by electron microscopy and revealed typical lysosomal inclusions with a concentric lamellar configuration in all four. Two patients had novel missense mutations in exon 1 and exon 6. The remaining five had no mutations in the coding region of the -galactosidase gene, but the amounts of the -galactosidase messenger RNA were markedly lower than normal.

Conclusions Seven unrelated patients with atypical variants of hemizygous Fabry's disease were found among 230 men with left ventricular hypertrophy. Fabry's disease should be considered as a cause of unexplained left ventricular hypertrophy.

Source Information

From the First Department of Internal Medicine (S.N., T.T., M.M., C.K., A.T., M.T., H.T.), the First Department of Pathology (A.Y.), and the Third Department of Internal Medicine (M.K.), Faculty of Medicine, Kagoshima University, Kagoshima, Japan; and the Department of Clinical Genetics, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan (H.H., H.S.).

Address reprint requests to Dr. Hiromitsu Tanaka at the First Department of Internal Medicine, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890, Japan.

Full Text of this Article

This article has been cited by other articles:

• Oqvist, B., Brenner, B. M., Oliveira, J. P., Ortiz, A., Schaefer, R., Svarstad, E., Wanner, C., Zhang, K., Warnock, D. G. (2009). Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transplant 24: 1736-1743 [Full Text]  
• De Cobelli, F., Esposito, A., Belloni, E., Pieroni, M., Perseghin, G., Chimenti, C., Frustaci, A., Del Maschio, A. (2009). Delayed-Enhanced Cardiac MRI for Differentiation of Fabry's Disease from Symmetric Hypertrophic Cardiomyopathy. Am. J. Roentgenol. 192: W97-W102 [Abstract] [Full Text]  
• Schoenmakere, G. D., Poppe, B., Wuyts, B., Claes, K., Cassiman, D., Maes, B., Verbeelen, D., Vanholder, R., Kuypers, D. R., Lameire, N., De Paepe, A., Terryn, W. (2008). Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrol Dial Transplant 23: 4044-4048 [Abstract] [Full Text]  
• Chimenti, C., Morgante, E., Tanzilli, G., Mangieri, E., Critelli, G., Gaudio, C., Russo, M. A., Frustaci, A. (2008). Angina in Fabry Disease Reflects Coronary Small Vessel Disease. Circ Heart Fail 1: 161-169 [Abstract] [Full Text]  
• Joshi, S. B., Ahmar, W., Lee, G., Aggarwal, A. (2008). Fabry's disease presenting as ventricular tachycardia and Left Ventricular 'Hypertrophy'. Eur J Echocardiogr 9: 697-699 [Abstract] [Full Text]  
• Kounas, S., Demetrescu, C., Pantazis, A. A., Keren, A., Lee, P. J., Hughes, D., Mehta, A., Elliott, P. M. (2008). The Binary Endocardial Appearance Is a Poor Discriminator of Anderson-Fabry Disease From Familial Hypertrophic Cardiomyopathy. J Am Coll Cardiol 51: 2058-2061 [Abstract] [Full Text]  
• Hughes, D A, Elliott, P M, Shah, J, Zuckerman, J, Coghlan, G, Brookes, J, Mehta, A B (2008). Effects of enzyme replacement therapy on the cardiomyopathy of Anderson Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94: 153-158 [Abstract] [Full Text]  
• Terryn, W., Poppe, B., Wuyts, B., Claes, K., Maes, B., Verbeelen, D., Vanholder, R., De Boeck, K., Lameire, N., De Paepe, A., De Schoenmakere, G. (2008). Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrol Dial Transplant 23: 294-300 [Abstract] [Full Text]  
• Andrade, J., Waters, P. J., Singh, R. S., Levin, A., Toh, B.-C., Vallance, H. D., Sirrs, S. (2008). Screening for Fabry Disease in Patients with Chronic Kidney Disease: Limitations of Plasma {alpha}-Galactosidase Assay as a Screening Test. CJASN 3: 139-145 [Abstract] [Full Text]  
• Monserrat, L., Gimeno-Blanes, J. R., Marin, F., Hermida-Prieto, M., Garcia-Honrubia, A., Perez, I., Fernandez, X., de Nicolas, R., de la Morena, G., Paya, E., Yague, J., Egido, J. (2007). Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 50: 2399-2403 [Abstract] [Full Text]  
• Ackerman, M. J., Landstrom, A. P. (2007). Detection of Subclinical Fabry Disease in Patients Presenting With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 50: 2404-2405 [Full Text]  
• Warnock, D. G. (2007). Enzyme Replacement Therapy and Fabry Kidney Disease: Quo Vadis?. J. Am. Soc. Nephrol. 18: 1368-1370 [Full Text]  
• Linhart, A., Elliott, P. M (2007). The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93: 528-535 [Full Text]  
• Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., Finkel, R., Packman, S., Bichet, D. G., Warnock, D. G., Desnick, R. J., for the Fabry Disease Clinical Trial Study Group*, (2007). Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial. ANN INTERN MED 146: 77-86 [Abstract] [Full Text]  
• Developed in Collaboration With the European Heart, , Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., Priori, S. G., Quinones, M. A., Roden, D. M., Silka, M. J., Tracy, C., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Antman, E. M., Anderson, J. L., Hunt, S. A., Halperin, J. L., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48: e247-e346 [Full Text]  
• Writing Committee Members, , Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., Priori, S. G., Quinones, M. A., Roden, D. M., Silka, M. J., Tracy, C., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Antman, E. M., Anderson, J. L., Hunt, S. A., Halperin, J. L., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8: 746-837 [Full Text]  
• Morita, H., Larson, M. G., Barr, S. C., Vasan, R. S., O'Donnell, C. J., Hirschhorn, J. N., Levy, D., Corey, D., Seidman, C. E., Seidman, J.G., Benjamin, E. J. (2006). Single-Gene Mutations and Increased Left Ventricular Wall Thickness in the Community: The Framingham Heart Study. Circulation 113: 2697-2705 [Abstract] [Full Text]  
• Pieroni, M., Chimenti, C., De Cobelli, F., Morgante, E., Del Maschio, A., Gaudio, C., Russo, M. A., Frustaci, A. (2006). Fabry's Disease Cardiomyopathy: Echocardiographic Detection of Endomyocardial Glycosphingolipid Compartmentalization. J Am Coll Cardiol 47: 1663-1671 [Abstract] [Full Text]  
• Morimoto, S.-i., Sugiura, A., Iwase, M., Kubo, N., Hiramitsu, S., Uemura, A., Ohtsuki, M., Kato, S., Kato, Y., Hishida, H. (2006). Relief of Left Ventricular Outflow Obstruction by Cibenzoline in a Patient With Fabry's Disease: A Case Report. ANGIOLOGY 57: 241-245 [Abstract]  
• Nance, C. S., Klein, C. J., Banikazemi, M., Dikman, S. H., Phelps, R. G., McArthur, J. C., Rodriguez, M., Desnick, R. J. (2006). Later-Onset Fabry Disease: An Adult Variant Presenting With the Cramp-Fasciculation Syndrome.. Arch Neurol 63: 453-457 [Abstract] [Full Text]  
• Yang, Z., McMahon, C. J., Smith, L. R., Bersola, J., Adesina, A. M., Breinholt, J. P., Kearney, D. L., Dreyer, W. J., Denfield, S. W., Price, J. F., Grenier, M., Kertesz, N. J., Clunie, S. K., Fernbach, S. D., Southern, J. F., Berger, S., Towbin, J. A., Bowles, K. R., Bowles, N. E. (2005). Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children. Circulation 112: 1612-1617 [Abstract] [Full Text]  
• De Backer, J., Matthys, D., Gillebert, T.C., De Paepe, A., De Sutter, J. (2005). The use of Tissue Doppler Imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies. Eur J Echocardiogr 6: 243-250 [Abstract] [Full Text]  
• Weidemann, F., Breunig, F., Beer, M., Sandstede, J., Stork, S., Voelker, W., Ertl, G., Knoll, A., Wanner, C., Strotmann, J. M. (2005). The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26: 1221-1227 [Abstract] [Full Text]  
• Arad, M., Maron, B. J., Gorham, J. M., Johnson, W. H. Jr., Saul, J. P., Perez-Atayde, A. R., Spirito, P., Wright, G. B., Kanter, R. J., Seidman, C. E., Seidman, J.G. (2005). Glycogen Storage Diseases Presenting as Hypertrophic Cardiomyopathy. NEJM 352: 362-372 [Abstract] [Full Text]  
• Larralde, M., Boggio, P., Amartino, H., Chamoles, N. (2004). Fabry Disease: A Study of 6 Hemizygous Men and 5 Heterozygous Women With Emphasis on Dermatologic Manifestations. Arch Dermatol 140: 1440-1446 [Abstract] [Full Text]  
• Chimenti, C., Pieroni, M., Morgante, E., Antuzzi, D., Russo, A., Russo, M. A., Maseri, A., Frustaci, A. (2004). Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy. Circulation 110: 1047-1053 [Abstract] [Full Text]  
• Charron, P, Villard, E, Sebillon, P, Laforet, P, Maisonobe, T, Duboscq-Bidot, L, Romero, N, Drouin-Garraud, V, Frebourg, T, Richard, P, Eymard, B, Komajda, M (2004). Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 90: 842-846 [Abstract] [Full Text]  
• Nagueh, S F (2003). Fabry disease. Heart 89: 819-820 [Full Text]  
• Ommen, S R, Nishimura, R A, Edwards, W D (2003). Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?. Heart 89: 929-930 [Full Text]  
• Pieroni, M., Chimenti, C., Ricci, R., Sale, P., Russo, M. A., Frustaci, A. (2003). Early Detection of Fabry Cardiomyopathy by Tissue Doppler Imaging. Circulation 107: 1978-1984 [Abstract] [Full Text]  
• Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., Grabowski, G., Packman, S., Wilcox, W. R. (2003). Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy. ANN INTERN MED 138: 338-346 [Abstract] [Full Text]  
• Breunig, F., Wanner, C. (2003). Enzyme replacement therapy for Fabry disease: proving the clinical benefit. Nephrol Dial Transplant 18: 7-9 [Full Text]  
• Tse, K.-C., Chan, K.-W., Tin, V. P.-C., Yip, P.-S., Tang, S., Li, F.-K., Ho, Y.-W., Lai, K.-N., Chan, T.-M. (2003). Clinical features and genetic analysis of a Chinese kindred with Fabry's disease. Nephrol Dial Transplant 18: 182-186 [Abstract] [Full Text]  
• Doi, Y, Toda, G, Yano, K (2003). Sisters with atypical Fabry's disease with complete atrioventricular block. Heart 89: e2-2 [Abstract] [Full Text]  
• Takahashi, H., Hirai, Y., Migita, M., Seino, Y., Fukuda, Y., Sakuraba, H., Kase, R., Kobayashi, T., Hashimoto, Y., Shimada, T. (2002). Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc. Natl. Acad. Sci. USA 99: 13777-13782 [Abstract] [Full Text]  
• Veinot, J. P., Elliott, P.M., Sachdev, B., McKenna, W.J., Takenaka, T., Teraguchi, H., Tei, C., Lee, P. (2002). Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy * Response. Circulation 106 : e73-e73 [Full Text]  
• MEHTA, A. (2002). New developments in the management of Anderson-Fabry disease. QJM 95: 647-653 [Abstract] [Full Text]  
• Grunfeld, J.-P., Chauveau, D., Levy, M. (2002). Anderson-Fabry Disease: Its Place among Other Genetic Causes of Renal Disease. J. Am. Soc. Nephrol. 13: S126-129 [Full Text]  
• Pastores, G. M., Lien, Y.-H. H. (2002). Biochemical and Molecular Genetic Basis of Fabry Disease. J. Am. Soc. Nephrol. 13: S130-133 [Full Text]  
• Kampmann, C., Baehner, F., Ries, M., Beck, M. (2002). Cardiac Involvement in Anderson-Fabry Disease. J. Am. Soc. Nephrol. 13: S147-149 [Full Text]  
• Frustaci, A., Pieroni, M., Chimenti, C. (2002). Late-onset primary LVH HCM versus cardiac fabry variant. J Am Coll Cardiol 39: 1405-1406 [Full Text]  
• Sachdev, B., Takenaka, T., Teraguchi, H., Tei, C., Lee, P., McKenna, W.J., Elliott, P.M. (2002). Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy. Circulation 105: 1407-1411 [Abstract] [Full Text]  
• Frustaci, A., Chimenti, C., Ricci, R., Natale, L., Russo, M. A., Pieroni, M., Eng, C. M., Desnick, R. J. (2001). Improvement in Cardiac Function in the Cardiac Variant of Fabry's Disease with Galactose-Infusion Therapy. NEJM 345: 25-32 [Full Text]  
• Brady, R. O., Schiffmann, R. (2000). Clinical Features of and Recent Advances in Therapy for Fabry Disease. JAMA 284: 2771-2775 [Abstract] [Full Text]  
• Lidove, O., Joly, D., Rossignol, P., Robino, C., N'Guessau, K., Grunfeld, J. P. (2000). A man with proteinuria, familial history of kidney disease, painful extremities and cutaneous lesions. Nephrol Dial Transplant 15: 433-435 [Full Text]  
• Bogardus, S. T. Jr, Concato, J., Feinstein, A. R. (1999). Clinical Epidemiological Quality in Molecular Genetic Research: The Need for Methodological Standards. JAMA 281: 1919-1926 [Abstract] [Full Text]  
• (1995). Fabry's Disease May Be a Cause of LVH in Some. Journal Watch Cardiology 1995: 14-14 [Full Text]  
• Takenaka, T., Murray, G. J., Qin, G., Quirk, J. M., Ohshima, T., Qasba, P., Clark, K., Kulkarni, A. B., Brady, R. O., Medin, J. A. (2000). Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc. Natl. Acad. Sci. USA 97: 7515-7520 [Abstract] [Full Text]